JAKAVI is now approved for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. Get important safety information at http://www.jakavi.com/Safety.jsp